Frankfurt, May 2014. CFP BioConnect – now ACXIT Capital Partners – acted as exclusive financial advisor to Artes Biotechnology GmbH, based in Langenfeld/Germany, on a strategic collaboration with Sun Pharmaceutical Industries, a multinational specialty pharmaceutical company with a diversified product portfolio, headquartered in Mumbai, India.
Artes Biotechnology owns proprietary technology platforms for recombinant proteins and vaccines. Several biopharmaceutical products and industrial enzymes have been successfully introduced to the international markets by its clients and licensees. Under the agreement with Sun Pharmaceutical Industries, Artes Biotechnology will develop cell lines and production processes for several pharmaceutical targets. Sun Pharmaceutical Industries will become a minority shareholder of Artes Biotechnology.
We are particularly proud to execute a transaction involving such a powerful pharma-ceutical company as Sun, the largest Indian pharmaceutical company by means of market capitalisation. It further demonstrates our ability to successfully complete M&A transactions with non-European companies and documents our international reach.
About Sun Pharma
Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. is an international specialty pharmaceutical company with over 70% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations both as branded generics and as generics in US, India and several other markets across the world. For the year ending March 2013, overall revenues were at US$2.1 billion, of which US contributed US$1.1 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, orthopaedics and ophthalmology. The company has strong skills in product development, process chemistry and manufacturing of complex dosage forms. (sunpharma.com)
About ARTES Biotechnology
ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld. The company focuses on contract R&D for red and white biotechnology products. (artes-biotechnology.com)
About ACXIT
ACXIT Capital Partners is a leading independent corporate finance and investment advisory firm for mid-market clients and entrepreneurs in Europe and beyond. Since 1998, ACXIT offers its clients comprehensive corporate finance advisory services including M&A and capital markets advisory as well as restructuring, equity/debt and strategic advisory. As an independent, privately owned firm we maintain offices and representations in Frankfurt, Berlin, Munich, Leipzig, Zurich, Hong Kong and New York, as well as strong alliances in France, China and India. (www.acxit.com)
PRESS CONTACT
ACXIT Capital Holding GmbH
WestendDuo
Bockenheimer Landstraße 24
60323 Frankfurt am Main
Germany
www.acxit.com
facebook.com/acxitcapital
twitter.com/acxitcapital
xing.com/companies/acxitcapitalpartners
linkedin.com/company/acxit-capital-partners
Dr. Hartmut Vennen
Senior Managing Director, Strategic Communications
FTI Consulting
Park Tower | Bockenheimer Anlage 44
60322 Frankfurt am Main
Phone: +49 69 92037 137
Mobile: +49 160 895 5858
E-mail: hartmut.vennen@fticonsulting.com
